Virus News and Research

Latest Virus News and Research

Presidio Pharmaceuticals completes Phase 1a clinical trial of PPI-461 in healthy subjects

Presidio Pharmaceuticals, Inc. announced today the successful completion of a Phase 1a clinical trial of PPI-461, its lead HCV NS5A inhibitor, in healthy subjects. This first-in-human trial evaluated four single doses of PPI-461, followed by a five-day, once-a-day treatment regimen with PPI-461 at the highest tested dose.

14 Jul 2010

Report urges multi-disciplinary research approach to help HIV-positive women stay healthy

A report issued by the Program on International Health and Human Rights at the Harvard School of Public Health proposes a new research agenda to address the sexual and reproductive health and rights of HIV-positive women.

14 Jul 2010

Scientists discover three human antibodies that neutralize HIV

Scientists have discovered three previously unknown human antibodies that neutralize HIV, two of which target a broad range of HIV strains. The findings, reported online July 8 in two Science papers, add a level of encouragement to the AIDS vaccine research field.

14 Jul 2010

IAS announces recipients of CNIHR grants

The International AIDS Society today announced the recipients of its first joint research grant programme, Creative and Novel Ideas in HIV Research. CNIHR grants, funded in partnership with the U.S. National Institutes of Health and the NIH-supported Centers for AIDS Research are designed to promote innovative research and new ideas from early stage investigators whose primary focus has previously been in fields of scientific inquiry other than HIV/ AIDS.

14 Jul 2010

U.N. report released ahead of International AIDS Conference: HIV prevalence drops among young Africans

The number of new HIV infections among young people in Africa is falling in most of the "25 countries hardest hit by the virus," according to a report released Tuesday by UNAIDS, the Associated Press reports (Cheng, 7/13).

14 Jul 2010

Administration to unveil first national HIV/AIDS strategy today

The White House will unveil the first formal national HIV/AIDS strategy on Tuesday, a plan that aims to reduce the number of new cases by 25 percent in the next five years, officials said. Noting that the number of new infections in the United States has been static -- and that the number of people living with HIV is growing -- the new policy would direct more resources toward African Americans and gay and bisexual men. Latinos and substance abusers should also be a priority, the report says.

14 Jul 2010

Opinions: Haitian rebuilding; Nuclear state vaccine initiatives; HIV rights abuses in China; HIV vaccine

The "paltry scale of the Pentagon's reconstruction endeavor [in Haiti] -- 1.6 million people displaced and the American military is contributing a few classrooms? -- is emblematic of the international response," columnist Dana Milbank writes in a Washington Post opinion piece.

14 Jul 2010

Today's OpEds: The Berwick backlash; HIV screening a part of routine care; And why Congress should provide Medicaid help to states

As is well-known, Congress has a constitutional duty to examine presidential nominees like Dr. Berwick. But apparently, the prospect of giving the American people an opportunity to hear this nominee defend his past praise for government-run systems that ration healthcare was worrisome enough for the administration that it sought to ignore congressional oversight altogether (Sen. Mitch McConnell, 7/12).

14 Jul 2010

First Edition: July 13, 2010

Today's health policy headlines include a report about state preparations to cut Medicaid spending as the federal funding stalemate continues and a status check on the start up of high-risk pools.

13 Jul 2010

ABL signs international distribution agreement for Virco BVBA's HIV resistance interpretation system

Advanced Biological Laboratories (ABL) is pleased to announce its recent signature of a non-exclusive international distribution agreement (excluding United States, Australia, Canada and United Kingdom) of virco®TYPE HIV-1, Belgium-based Virco BVBA's HIV resistance interpretation system.

13 Jul 2010

Researchers watch armed tumor-seeking immune system cells attack dangerous melanomas in real time

Researchers at UCLA's Jonsson Comprehensive Cancer Center created a large, well armed battalion of tumor-seeking immune system cells and watched, in real time using Positron Emission Tomography (PET), as the special forces traveled throughout the body to locate and attack dangerous melanomas.

13 Jul 2010

Inadequate funding for research, prevention will not help eradicate HIV in Quebec

On the XVIII International AIDS Conference's Eve (Vienna, Austria, July 18th to 23rd 2010), Mark Wainberg, PhD, co-director at Réseau Sida/Maladies infectieuses (FRSQ) and Dr. Réjean Thomas, president of clinique médicale l'Actuel denounce chronic underfunding in research and prevention related to HIV in Quebec and it's dramatic impact on the HIV epidemic and STI's. Researchers insist that the government double the amounts dedicated to these sectors.

13 Jul 2010

Sewage that overflows into urban creeks, streams can promote spread of West Nile virus: Study

Sewage that overflows into urban creeks and streams during periods of heavy rain can promote the spread of West Nile virus, a study led by Emory University finds. The analysis of six years of data showed that people living near creeks with sewage overflows in lower-income neighborhoods of Southeast Atlanta had a seven times higher risk for West Nile virus than the rest of the city.

13 Jul 2010

Biomagnetics signs LOI to acquire Lanzhou Sanhuan New Technology Development

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, and other innovative technologies, today announced the signing of a Letter of Intent (LOI) with Lanzhou Sanhuan New Technology Development Ltd. of Ganzu, China. This expected acquisition is the first of several planned acquisitions targeted at a $1.00 share price for Biomagnetics Diagnostics' common shares.

12 Jul 2010

Report on program to develop, test nasally delivered H5N1 vaccine filed with Japan's MHLW

Hemispherx Biopharma, Inc., announced that it has received a report, prepared by Hideki Hasegawa, M.D. Ph.D., Director, Laboratory of Infectious Disease Pathology, National Institute of Infectious Disease, that summarizes the results of a three year Japanese government funded program to develop and test a nasally delivered H5N1 (Avian Flu) vaccine which, when coupled with Ampligen®, an experimental therapeutic, provided a robust and long lasting immune response to the vaccine.

12 Jul 2010

Medivir reports 24-week interim Phase 2b results of TMC435 in treatment-naïve patients with HCV genotype-1

Medivir announced today 24-week end-of-treatment interim results from the 5-arm phase 2b response guided PILLAR study in 386 treatment-naïve patients with hepatitis C virus (HCV) genotype-1 (TMC435-C205).

12 Jul 2010

Lectures on DermaVir to be presented at International Conference on Nanosciences & Nanotechnologies

Julianna Lisziewicz, PhD, President of Genetic Immunity, a biopharmaceutical company developing nanomedicine-based immunotherapies, is an invited speaker at this week's 7th International Conference on Nanosciences & Nanotechnologies in Ouranoupolis Halkidiki, Greece. The conference gathers front-line researchers, scientists and industry experts specialized in nanotechnology applications. Leading experts such as Dr. Lisziewicz are invited to present lectures covering the latest research in this rapidly progressing field.

12 Jul 2010

Midatech, Immunotope form joint venture to develop antigen based products for immune therapies

Midatech Group Ltd., a global leader for the design, development, synthesis and manufacture of nanomedicines, and Immunotope Inc, a biotechnology company focused on the development of immunotherapy products, today announced the formation of a joint venture Syntara LLC, to develop antigen based products for immune therapies to treat chronic viral infections and certain cancers.

12 Jul 2010

Discovery of antibodies that kill more than 90% of HIV viruses gives new hope for vaccine

"An effective vaccine against the AIDS virus may have moved one step closer to reality, researchers said Thursday," the Los Angeles Times reports. "Federal researchers have identified a pair of naturally occurring antibodies that are able to kill more than 90% of all strains of the AIDS virus, a finding they say could lead to the development of new treatments for HIV infections and to the production of the first successful vaccine against the virus" (Maugh, 7/9).

12 Jul 2010

Science special section examines HIV/AIDS in Russia, Ukraine

In a special section in advance of the International AIDS Conference, Science examines the "state of the HIV/AIDS epidemic in Russia and Ukraine, which account for more than 90% of HIV infections in Eastern Europe."

12 Jul 2010

Virus News and Research

Latest Virus News and Research

Presidio Pharmaceuticals completes Phase 1a clinical trial of PPI-461 in healthy subjects

Report urges multi-disciplinary research approach to help HIV-positive women stay healthy

Scientists discover three human antibodies that neutralize HIV

IAS announces recipients of CNIHR grants

U.N. report released ahead of International AIDS Conference: HIV prevalence drops among young Africans

Administration to unveil first national HIV/AIDS strategy today

Opinions: Haitian rebuilding; Nuclear state vaccine initiatives; HIV rights abuses in China; HIV vaccine

Today's OpEds: The Berwick backlash; HIV screening a part of routine care; And why Congress should provide Medicaid help to states

First Edition: July 13, 2010

ABL signs international distribution agreement for Virco BVBA's HIV resistance interpretation system

Researchers watch armed tumor-seeking immune system cells attack dangerous melanomas in real time

Inadequate funding for research, prevention will not help eradicate HIV in Quebec

Sewage that overflows into urban creeks, streams can promote spread of West Nile virus: Study

Biomagnetics signs LOI to acquire Lanzhou Sanhuan New Technology Development

Report on program to develop, test nasally delivered H5N1 vaccine filed with Japan's MHLW

Medivir reports 24-week interim Phase 2b results of TMC435 in treatment-naïve patients with HCV genotype-1

Lectures on DermaVir to be presented at International Conference on Nanosciences & Nanotechnologies

Midatech, Immunotope form joint venture to develop antigen based products for immune therapies

Discovery of antibodies that kill more than 90% of HIV viruses gives new hope for vaccine

Science special section examines HIV/AIDS in Russia, Ukraine

A new way of characterising biomolecules eBook

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Newsletters you may be interested in